COVID-19 by SARS-CoV-2 Infection Clinical Trial
Official title:
Prevalence and Clinical Evolution of Olfactory and Taste Disorders in Patients Infected by SARS-CoV-2
Verified date | April 2020 |
Source | Centre Hospitalier Universitaire de Nice |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
A novel coronavirus SARS-CoV-2 HAS arose in 2019 in Wuhan, China. Beside the classical semiology of this infection, numerous patients described olfactory and teste disorders. These symptoms are not described in this coronavirus, neurotropism of coronaviridae has been documented before. The aim of the study is to evaluate prevalence of anosmia and dysgeusia (olfactory and taste disorders) in coronavirus diagnosed patients and compare with different clinical conditions. The second endpoint is to evaluate the duration of these symptoms in order to better understand the semiology of this infection.
Status | Enrolling by invitation |
Enrollment | 50 |
Est. completion date | May 31, 2020 |
Est. primary completion date | April 10, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A and older |
Eligibility |
Inclusion Criteria: - COVID-19 diagnosed |
Country | Name | City | State |
---|---|---|---|
France | CHU de Nice | Nice |
Lead Sponsor | Collaborator |
---|---|
Centre Hospitalier Universitaire de Nice |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Anosmia | Prevalence for anosmia in the COVID-19 + patients | 45 days | |
Primary | Ageusia | Prevalence for ageusia in the COVID-19 + patients | 45 days | |
Primary | Duration of the loss of anosmia ageusia | Duration measured in days | 45 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04371510 -
Blood Biomarkers as Predictors of COVID-19 Disease Progression in Recently Infected Chronic Haemodialysis Patients
|
N/A | |
Completed |
NCT04385017 -
Role of Inflammasomes in COVID-19 Disease
|
N/A |